Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. proskit

PROSKit SIGNED

Prostate cancer urinary diagnostic kit based on RNA biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROSKit project word cloud

Explore the words cloud of the PROSKit project. It provides you a very rough idea of what is the project "PROSKit" about.

intact    home    lab    analysed    temperature    validate    weeks    tested    diagnosis    segment    tools    requiring    minutes    samples    ready    specificity    reduce    throughput    extend    cancer    dna    biomarkers    prostate    hours    biotechnology    rna    certify    preserving    collect    proposing    biomarker    perform    lt    protocol    molecular    respect    stabilise    collection    11    blood    discriminative    collected    kits    billion    mix    core    gt    patented    sensitivity    unstable    inexpensive    2025    preparation    market    chemicals    informative    stability    environment    central    validated    arcis    capability    pca3    positive    85    patient    diagnostic    holdings    urine    unnecessary    28    platform    10    room    patients    psa    stabilization    price    assay    accurate    care    days    surgery    sampling    specialized    revenues    biopsies    device    acids    tests    competitors    laboratory    anywhere    nucleic    invasively    proprietary    poc    proskit    false    60    validation    offers    biopsy    rapid    clinical    amplifiable    14    business    simultaneously    thousands    license    point    location   

Project "PROSKit" data sheet

The following table provides information about the project.

Coordinator		 ARCIS BIOTECHNOLOGY HOLDINGS LIMITED 

Organization address
address: SUITE F42, THE INNOVATION CENTRE KECKWICK LANE
city: DARESBURY WARRINGTON
postcode: WA4 4FS
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARCIS BIOTECHNOLOGY HOLDINGS LIMITED UK (DARESBURY WARRINGTON) coordinator 50˙000.00

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More